Aerocrine AB is a medical technology concern focused on the improved
management and care of patients with airway inflammation. The
company markets NIOX Flex globally, and also markets NIOX MINO in
Both products enable fast and reliable management of airway
inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of asthma patients.
The founders of Aerocrine emerged from the highly prestigious
Karolinska Institute in Sweden where they were the first to identify
nitric oxide (NO) as a marker of inflammation.
Aerocrine is based in Sweden with subsidiaries in the US, Germany
and the UK.